Flixotide輔舒酮

Flixotide

fluticasone

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Fluticasone propionate
Indications/Uses
Adults & adolescents ≥16 yr Prophylactic management in mild asthma Patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. Moderate asthma Patients requiring regular asthma medication & patients w/ unstable or worsening asthma on currently available prophylactic therapy or bronchodilator alone. Severe asthma Patients w/ severe chronic asthma. On introduction of inhaled fluticasone propionate many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or to eliminate their requirement for oral corticosteroids. Childn ≥12 mth Any child who requires preventive asthma medication, including patients not controlled on currently available prophylactic medication.
Dosage/Direction for Use
Adult & adolescent ≥16 yr 100-1,000 mcg bd. Mild asthma 100-250 mcg bd. Moderate asthma 250-500 mcg bd. Severe asthma 500-1,000 mcg bd. Childn 4-16 yr 50-200 mcg bd, 12 mth to 4 yr 100 mcg bd via paed spacer device w/ a face mask.
Contraindications
Special Precautions
Reassess patient's therapy plan in case of deterioration of asthma control. Not for use in acute asthma attacks. Lack of response or severe exacerbations of asthma may be treated by increasing the dose. Systemic effects may occur w/ any inhaled corticosteroid, particularly at high doses prescribed for long periods. Growth of paed patients receiving corticosteroids (especially prolonged treatment) should be monitored. Patients in a medical or surgical emergency w/ past medication history of high doses of other inhaled steroids &/or intermittent treatment w/ oral steroids. Patients transferring from oral to inhalation therapy should be treated w/ special care & adrenocortical function regularly monitored. Replacement of systemic steroid treatment w/ inhaled therapy may unmask allergies previously controlled by the systemic drug. Do not stop treatment abruptly. Patients w/ a history of DM; active or quiescent pulmonary TB. Discontinue if paradoxical bronchospasm occurs. Avoid concomitant use w/ ritonavir. Pregnancy & lactation. Childn.
Adverse Reactions
Candidiasis (thrush) of mouth & throat. Hoarseness; contusions. Cutaneous hypersensitivity reactions. Oesophageal candidiasis; angioedema (mainly facial & oropharyngeal oedema), resp symptoms (dyspnoea &/or bronchospasm); adrenal suppression, growth retardation in childn & adolescents, decrease in bone mineral density, cataract, glaucoma, Cushing's syndrome & Cushingoid features; paradoxical bronchospasm. Anaphylactic reactions; anxiety, sleep disorders & behavioural changes, including hyperactivity & irritability (predominantly in childn); hyperglycaemia.
Drug Interactions
Greatly increased plasma conc w/ ritonavir. Minor increase in systemic exposure w/ ketoconazole. Potentially increased systemic exposure w/ other potent CYP3A4 inhibitors.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03BA05 - fluticasone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
Presentation/Packing
Form
Flixotide inhaler 125 mcg/actuation
Packing/Price
60 actuation x 1's
Form
Flixotide inhaler 250 mcg/actuation
Packing/Price
120 actuation x 1's
Form
Flixotide inhaler 50 mcg/actuation
Packing/Price
(CFC-free) 120 actuation x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in